<DOC>
	<DOCNO>NCT00190489</DOCNO>
	<brief_summary>To investigate clinical benefit Docetaxel alternate AC-Docetaxel comparison standard AC metastatic breast cancer</brief_summary>
	<brief_title>A Trial Doxorubicin/Cyclophosphamide ( AC ) , Docetaxel ( D ) , Alternating AC D Metastatic Breast Cancer</brief_title>
	<detailed_description>power detect 50 % increase median TTF 0.025 one-sided alpha AC vs. D AC vs. AC-D . Results : 441pts ( 146 AC , 147 D , 148 AC-D ) randomize 01/99 05/03 . Major grade 3-4 toxicity neutropenia ( 26/45/46 % AC/D/AC-D ) , febrile neutropenia ( 3/4/6 % ) , nausea/vomiting ( 3/3/4 % ) . There toxic death . One grade 4 diarrhea AC-D 1 secondary leukemia ( APL ) D report . Response ( CR/PR ) rate 30 , 41 , 35 % AC , D , AC-D respectively . Median TTF ( AC , D , AC-D ) 6.4 , 6.4 , 6.7 month ( p =.255 AC vs. D , p =.275 AC vs. AC-D ) , median overall survival 22.4 , 25.7 , 25.0 month ( p=.092 AC vs. D , p=.076 AC vs. AC-D ) . The difference show adjusted Cox model . Conclusions : No benefit demonstrate D AC-D AC TTF , however , D AC-D tend superior AC response rate overall survival . Survival benefit front-line docetaxel re-evaluated long follow-up .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Hormonal therapyresistant MBC 2 . ER ( ) , failure hormonal therapy MBC , relapse within 6 month adjuvant hormonal therapy 3 . No anthracyclines MBC prior taxanes 4 . At least 6 month completion adjuvant chemotherapy 5 . Measurable evaluable lesion 6 . Age : 20 75 year 7 . PS : 03 8 . WBC &gt; = 4,000 /mm3 ANC &gt; =1,000 /mm3 , Platelet &gt; = 100,000 /mm3 , SGOT/SGPT &lt; = 1.5 x ULN , TBil &lt; = 1.5 mg/dL , Cr &lt; = 1.5 mg/dL 9. normal ECG 10 . Written inform consent 1. pregnant 2. malignant pleural effusion , ascites , pericardial effusion require emergent treatment 3 . Active infection 4. cancer present within last 5 year 5. previous stem cell transplantation 6. brain metastasis require emergent treatment 7. relapse within 6 month completion anthracycline anthracycline 8. 250mg/m2 anthracyclines 9. hypersensitivity drug 10. interstitial pneumonitis pulmonary fibrosis 11. positive HBs 12. antipsychotic medication 13. doctor 's judgement</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>metastatic breast cancer</keyword>
	<keyword>drug therapy</keyword>
	<keyword>doxorubicin</keyword>
	<keyword>docetaxel</keyword>
</DOC>